Intec Pharma Ltd. (NASDAQ:NTEC) and Neon Therapeutics Inc. (NASDAQ:NTGN) compete with each other in the Biotechnology sector. We will analyze and contrast their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Intec Pharma Ltd.||N/A||0.00||43.54M||-1.40||0.00|
|Neon Therapeutics Inc.||N/A||0.00||83.31M||-2.75||0.00|
Table 1 highlights Intec Pharma Ltd. and Neon Therapeutics Inc.’s top-line revenue, earnings per share and valuation.
Table 2 provides us the return on equity, return on assets and net margins of both companies.
|Net Margins||Return on Equity||Return on Assets|
|Intec Pharma Ltd.||0.00%||0%||0%|
|Neon Therapeutics Inc.||0.00%||-545.4%||-69.6%|
Institutional & Insider Ownership
The shares of both Intec Pharma Ltd. and Neon Therapeutics Inc. are owned by institutional investors at 39.64% and 70.1% respectively. About 11.81% of Intec Pharma Ltd.’s share are owned by insiders. On the other hand, insiders owned about 16.29% of Neon Therapeutics Inc.’s shares.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Intec Pharma Ltd.||-5.95%||4.85%||37.69%||116.32%||34.75%||9.02%|
|Neon Therapeutics Inc.||22.03%||47.64%||1.29%||-45.99%||0%||24.45%|
For the past year Intec Pharma Ltd. was less bullish than Neon Therapeutics Inc.
Intec Pharma Ltd. beats Neon Therapeutics Inc. on 4 of the 6 factors.
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The companyÂ’s lead product candidate is Accordion Pill Carbidopa/Levodopa (AP-CDLD), which is in a Phase III clinical trial for the treatment of ParkinsonÂ’s disease symptoms in advanced ParkinsonÂ’s disease patients. It is also developing Accordion Pill Zaleplon (AP-ZP) that is in a Phase III clinical trial for the treatment of insomnia, including sleep induction and for enhancing of sleep maintenance; Accordion Pill, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and Accordion Pill platform with Cannabidiol and 9-Tetrahydrocannabinol, (AP-CBD/THC), which is in a Phase I clinical trial for the treatment of various indications, including low back neuropathic pain and fibromyalgia. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.
Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.